Primary:
To determine maximum tolerated dose & dose limiting toxicity of dasatinib when combined w
erlotinib among pts w recurrent MG
Secondary:
To further evaluate safety & tolerability of dasatinib + erlotinib To evaluate
pharmacokinetics of dasatinib when administered w erlotinib among recurrent MG pts who are on
& not on CYP-3A enzyme inducing anti-epileptic drugs To evaluate for anti-tumor activity with
this regimen in this patient population